OMNIlife science, Inc. Announces The Appointment Of Steven Nunes As Senior Vice President Of Sales And Marketing

EAST TAUNTON, Mass., April 15, 2015 /PRNewswire/ -- OMNIlife science, Inc. ("OMNI"), is an established medical technology company targeting the $15 billion and rapidly growing global hip and knee replacement medical device sector. They proudly offer the only commercially available surgical robotic system to enhance the surgeon's implant placement for total knee replacements, the OMNINAV™. Today OMNI announces that Steven Nunes has been appointed Senior Vice President of Sales and Marketing. In this expanded role, Mr. Nunes will also be responsible for Global Sales and Product Marketing Management in addition to the Robotics Market Development responsibilities he has been managing.

Mr. Nunes, who joined OMNI in December, 2014, brings more than 30 years of broad Sales and Marketing management experience at emerging growth medical device companies. Most relevant to OMNI is his experience as Senior Vice President of Sales and Marketing at MAKO Surgical. During his tenure at MAKO, Mr. Nunes led the Sales and Marketing effort which resulted in orthopedic robotic and hip and knee implant product revenue growth from $0.5 to $85 million during a five year time span. MAKO was ultimately acquired by Stryker Corp. for $1.65 billion.

Rick Randall, Chief Executive Officer of OMNI commented, "Steve has developed a commercial strategy aimed to strengthen OMNI's leadership in the emerging field of Robotic Assisted Total Knee and Hip Replacement. It is now time to consolidate the remaining sales and product marketing disciplines under his leadership to ensure the execution of our plan for sustained revenue growth. Changing the face of Orthopaedic Surgery requires strategic selling, high-level surgeon training, product and procedural marketing and world-class customer service. Steve understands the complexity of the task and has successfully built highly functional Sales and Marketing Teams to address these needs in the past."

Regarding his expanded role at OMNI, Mr. Nunes commented, "I am very excited to take on these additional responsibilities and have enjoyed working with all the passionate people at OMNI. My experience in the first few months here has only reinforced my belief that we are in a great position to deliver the significant value that robotic technology can bring to patients, surgeons, hospitals and all other stakeholders in the healthcare system."

About OMNIlife science, Inc. (OMNI)

OMNI is a privately held company with a proprietary robotic navigation platform, OMNINAV™, which allows surgeons to conduct patient specific total knee surgery designed to enhance patient satisfaction, reduce hospital costs, and remove need for MRI and x-rays. This technology provides surgeons the much needed option to adjust during the procedure and is designed to provide an accurate customized fit. OMNI is an innovative and well-established hip and knee implant replacements engineering, manufacturing and distribution support company and is focused on providing cutting edge technologies to improve patient care.

Forward-Looking Statements

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., (OMNI) including its advance robotic plans and statements using the terms "plans," "confident" or similar expressions are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI's markets, decrease in the demand for OMNI's products, delays in OMNI's product research and development cycles, decreases in the use of OMNI's principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI's current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI's current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI's sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI's products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward looking statements after the date of this press release

Contact:

OMNIlife science, Inc. (OMNI)
Kirsten Wyzanski
Director of Marketing Communications
Phone: (508) 824-2444

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/omni-announces-the-appointment-of-steven-nunes-as-senior-vice-president-of-sales-and-marketing-300065917.html

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.